CL2014001263A1 -
Bispecific binding molecule for bcma and cd3; nucleic acid sequence that encodes it; vector; cell; pharmaceutical composition comprising the binding molecule; use to treat diseases related to plasma cell disorders, b cell disorders correlated with bcma expression and autoimmune diseases.
- Google Patents
Bispecific binding molecule for bcma and cd3; nucleic acid sequence that encodes it; vector; cell; pharmaceutical composition comprising the binding molecule; use to treat diseases related to plasma cell disorders, b cell disorders correlated with bcma expression and autoimmune diseases.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=52002373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014001263(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int, Amgen Res Munich GmbhfiledCriticalBoehringer Ingelheim Int
Publication of CL2014001263A1publicationCriticalpatent/CL2014001263A1/en
CL2014001263A2011-11-152014-05-14
Bispecific binding molecule for bcma and cd3; nucleic acid sequence that encodes it; vector; cell; pharmaceutical composition comprising the binding molecule; use to treat diseases related to plasma cell disorders, b cell disorders correlated with bcma expression and autoimmune diseases.
CL2014001263A1
(en)
Bispecific binding molecule for bcma and cd3; nucleic acid sequence that encodes it; vector; cell; pharmaceutical composition comprising the binding molecule; use to treat diseases related to plasma cell disorders, b cell disorders correlated with bcma expression and autoimmune diseases.
Bispecific binding molecule for bcma and cd3; nucleic acid sequence that encodes it; vector; cell; pharmaceutical composition comprising the binding molecule; use to treat diseases related to plasma cell disorders, b cell disorders correlated with bcma expression and autoimmune diseases.
Heteroaromatic compounds, btk inhibitors, pharmaceutical composition that comprises them and use in diseases such as rheumatoid arthritis, lupus, among others.
Binding protein that has the ability to bind interleukin 1beta and interleukin 17; crystallized binding protein conjugate; nucleic acid, vector, host cell; method to produce a binding protein; pharmaceutical composition comprising the binding protein.
Binding molecule that binds to cd134 (ox40); nucleic acid molecule that encodes it; vector; host cell; Preparation process; pharmaceutical composition that includes it; and its use to treat cancer.
Selection procedure for anti-cxcr4 antibodies and selected antibodies; nucleic acid encoding the antibodies; vector; host cell; production procedure; hybridoma that produces the antibodies; composition; use of selected antibodies to prepare a medicine to treat cancer.
Cx3cr1 binding polypeptides; nucleic acid molecule that encodes it; pharmaceutical composition that contains it; method of elaboration of the peptide; uses of the peptide; kit containing the peptide.
Binding molecule that specifically binds inteleukin 6 (il-6); pharmaceutical composition comprising it; nucleic acid; vector; host cell; and use to treat disease or disorder associated with il-6.
Bispecific binding molecule for bcma and cd3; nucleic acid sequence that encodes it; vector; cell; pharmaceutical composition comprising the binding molecule; use to treat diseases related to plasma cell disorders, b cell disorders correlated with bcma expression and autoimmune diseases.